Business Description
Medibio Ltd
NAICS : 541711
ISIN : AU000000MEB8
Description
TrivarX Ltd is a health technology company developing AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions. Trivarx's clinical research has enabled the development of cutting-edge proprietary algorithms for spectral analyses of sleep architecture and heart rate variability.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 53 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 38.3 | |||||
| 3-Year EPS without NRI Growth Rate | 41.5 | |||||
| 3-Year FCF Growth Rate | 37 | |||||
| 3-Year Book Growth Rate | -49.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -58.82 | |||||
| 12-1 Month Momentum % | -70 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.78 | |||||
| Quick Ratio | 0.78 | |||||
| Cash Ratio | 0.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -65.9 | |||||
| Shareholder Yield % | -57.65 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -17.47 | |||||
| ROA % | -15.1 | |||||
| ROIC % | -25.03 | |||||
| 3-Year ROIIC % | -7.06 | |||||
| ROC (Joel Greenblatt) % | -2350.55 | |||||
| ROCE % | -17.36 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.75 | |||||
| EV-to-EBIT | -5.19 | |||||
| EV-to-EBITDA | -5.55 | |||||
| EV-to-FCF | -1.86 | |||||
| Earnings Yield (Greenblatt) % | -19.27 | |||||
| FCF Yield % | -48.33 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Medibio Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | 0 | ||
| Beta | 0 | ||
| Volatility % | 148.45 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0.000643 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | -70 | ||
| 52-Week Range (€) | 0.0025 - 0.01 | ||
| Shares Outstanding (Mil) | 1,795.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Medibio Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Medibio Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Medibio Ltd Frequently Asked Questions
What is Medibio Ltd(STU:BPN)'s stock price today?
The current price of STU:BPN is €0.00. The 52 week high of STU:BPN is €0.01 and 52 week low is €0.00.
When is next earnings date of Medibio Ltd(STU:BPN)?
The next earnings date of Medibio Ltd(STU:BPN) is 2025-02-28 Est..
Does Medibio Ltd(STU:BPN) pay dividends? If so, how much?
Medibio Ltd(STU:BPN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers